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In this study, the cell free modified tryptone soya broth (pH 7.4 ± 0.2) of Bacillus subtilis
URID 12.1 showed significant antimicrobial activity against multidrug-resistant strains
of Staphylococcus aureus, S. epidermidis, Streptococcus pyogenes and Enterococcus
faecalis. The partially purified antimicrobial molecule was found to be resistant to
extremes of pH and temperatures and also to higher concentrations of trypsin and
proteinase K. The antimicrobial molecule was purified by a three-step method that
included reversed-phase high performance liquid chromatography (RP-HPLC). The
minimum inhibitory concentration (MIC) values were determined for 14 species of bacteria
using a microbroth dilution technique. The HPLC-purified fraction showed the MICs
ranging from 0.5 to 16µg/ml for methicillin and vancomycin-resistant Staphylococcus
aureus (MVRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE) strains.
The molecular mass of the antimicrobial compound was determined to be 842.37 Da.
The same antimicrobial fraction showed negligible haemolytic activity against human red
blood cells even at a concentration as high as 100µg/ml. Because of its significant
antimicrobial activity at low MIC values coupled with its non-haemolytic property, it may
prove to be a novel antimicrobial lead molecule.
Keywords: promising antimicrobial agent, Bacillus sp., multidrug resistant-bacteria, minimum inhibitory
concentration, Staphylococcus aureus, non-haemolytic property
INTRODUCTION
Antimicrobial peptides (AMPs) represent a defense system against invading pathogenic bacteria
and are effective therapeutically against antibiotic-resistant bacteria by causing rapid killing.
Nonribosomal peptides represent a large family of bioactive secondary metabolites produced by
bacteria and fungi. Many of these peptides turned out to be important antibiotics like iturin,
gramicidin, and bacitracin. The production of antibiotics is considered to be a major step in
enhancing the competitiveness of producing organism under an environment with limited resource
(Grossman, 1995). Bacillus is an important genus producing an umpteen number of ribosomal
and nonribosomal peptides with bioactivity (Tamehiro et al., 2002). For example, nonribosomal
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peptides are derived from Bacilli (Emmert et al., 2004; Kessler
et al., 2004; Ehling-Schulz et al., 2005); peptide antibiotics are
a predominant class of antimicrobial molecules produced by B.
subtilis species (Hagelin et al., 2004; Stein, 2005). In addition, the
peptides can further be modified by N-methylation, acylation,
glycosylation, or heterocyclization, so they have clear advantages
over ribosomally synthesized peptides in structural diversity
(Von Döhren, 1995; Wu et al., 2006). Bacilli are especially known
for their ability to produce a wide variety of bioactive compounds
and wild-type B. subtilis strains particularly are armed with a
battery of chemically diverse antimicrobial compounds which
include non-ribosomally synthesized peptides (Vanittanakom
et al., 1986; Von Döhren, 1995; Hagelin et al., 2004; Kessler
et al., 2004; Stein, 2005; Wu et al., 2006), such as polymyxins
and the lipopeptide surfactin, gene encoded bacteriocins, such
as subtilosin and, within this latter group, lantibiotic, such as
subtilin (Von Döhren, 1995; Stein, 2005).
The continued prevalence of methicillin-resistant
Staphylococcus aureus (MRSA) and S. epidermidis (MRSE)
infections represents a major clinical challenge. Interestingly last
two decades have witnessed a dramatic increase of vancomycin
and teicoplanin resistance of methicillin-resistant Staphylococcus
species in several hospitals around the world (Isnansetyo and
Kamei, 2003; Tabarez et al., 2006). The natural environment
remains an important reservoir for microorganisms capable of
producing newer potent antimicrobials (Clardy et al., 2006).
A narrow-spectrum but strong antibacterial compound has
been recently purified from the cell-free supernatant of soil-
bacterium belonging to the genus Bacillus and was found to have
potent antimicrobial activity against several clinically important
drug-resistant pathogens including methicillin-vancomycin-
resistant Staphylococcus aureus (MVRSA), MRSA, MRSE, and
vancomycin-resistant Enterococcus faecalis (VRE). The present
communication addresses the purification and various aspects of
anti-Staphylococcus activity of the reversed-phase HPLC-purified
fraction along with an evaluation of its overall antibacterial
activities.
METHODS
Microbial Cultures, Media, and Growth
Conditions
The wild-type soil-isolate (URID 12.1) showing antimicrobial
activity was grown in modified Tryptone Soya Broth (mTSB, with
0.5% yeast extract) at 37◦C under shaking conditions (110 rpm).
All indicator bacterial strains (Tables 1, 4) including the quality
control strains S. aureus ATCC 29213 and S. aureus MTCC 737
(ATCC 6538P) and E. faecalis ATCC 29212, were subcultured
in Mueller-Hinton and Brain Heart Infusion (BHI) broths at
37◦C. The quality control strains S. aureus ATCC 29213 and E.
faecalis ATCC 29212 were obtained from OncQuest Laboratory,
Indore, whereas the S. aureus MTCC 737 (ATCC 6538P) was
procured from the Microbial Type Culture Collection (MTCC),
Chandigarh, India. All the cultures used as indicator strains
(Tables 1, 4) were obtained from the MTCC, Chandigarh and
National Collection of IndustrialMicroorganisms (NCIM), Pune,
TABLE 1 | Antimicrobial activity of URID 12.1 by cut well agar diffusion
assay using the CFS at 44h of growth.
Strain
number
Indicator organisms Zone of inhibition
(diameter) in mm
1 Methicillin and vancomycin resistant
Staphylococcus aureus 4*
25
2 Methicillin-resistant S. aureus 2* 22
3 S. aureus-GMC* 23
4 S. aureus MTCC 96 26
5 S. aureus MTCC 737 (ATCC 6538P) 21
6 S. aureus MTCC 5021 18
7 Micrococcus luteus MTCC 2170 25
8 Methicillin-resistant Staphylococcus
epidermidis 3*
26
9 Staphylococcus epidermidis ATCC 12228 27
10 Vancomycin-resistant Enterococcus
faecium 13
17
11 Streptococcus pyogenes MTCC 442 22
12 S. pyogenes MTCC 1928 16
13 S. pyogenes NCIM 2608 18
14 Escherichia coli MTCC 723 No zone
15 Klebsiella pneumoniae No zone
16 Acinetobacter baumannii MTCC 1425 No zone
17 Salmonella Infantis MTCC 1167 No zone
*Indicates clinical strains.
and the clinical isolates from the Central Laboratory, OncQuest
Laboratory, Indore, and S. aureus GMC from Goa Medical
College, India. The cultures were also maintained as 20% glycerol
stocks at −80◦C. The antimicrobial susceptibilities of the quality
control strains were tested using oxacillin and vancomycin.
Screening for Antimicrobial Activity
The spot-on-lawn method was used for the bioassay of
antimicrobial activity. Bacterial strain S. aureus MTCC 737 was
used as indicator initially for the screening purpose. Soil samples
were serially diluted in sterile 0.85% saline and spread to obtain
single colonies. The colonies were inoculated into fresh TSB
and the supernatant was collected after 24–48 h incubation.
Freshly grown overnight indicator strain wasmixedwith soft agar
(0.7%) and the mixture was transferred to plates prepoured with
1.8% agar. The supernatant was spotted, plates were incubated
at 37◦C for 24–48 h and inspected for the zone of inhibition.
The wild-type bacterial isolate showing consistently reproducible
antibacterial activity against the indicator strain was initially
designated as Bacillus sp. URID 12 used for the construction
of phylogenetic tree with the producer strain used in a separate
study (Ramya et al., 2013).
Identification of the Producer Strain
Bacillus sp. URID 12.1
PCR Based Identification
Genomic DNA of the isolate URID 12.1 was extracted from
overnight grown culture by using the method after (Neumann
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et al., 1992). The genomic DNA was used to perform the 16S
rRNA sequencing PCR by using the primers “fwd_name: 27F,
fwd_seq: AGAGTTTGATCCTGGCTCAG, rev_name: 1492r,
rev_seq: GGTTACCTTGTTACGACTT” for 16S rDNA-based
identification. The amplified product was sequenced and
analyzed using the NCBI BLAST. The phylogenetic tree
was constructed using Mega 5.0 software (Tamura et al.,
2011). Databases (GenBank) were used for sequence similarity
comparison with the 16S rDNA sequence obtained. The
identified strain has been redesignated as B. sutbtilis URID 12.1.
MALDI-TOF (Matrix-assisted Laser
Desorption/Ionization-time of Flight)
Biotyper
Ethanol/Formic Acid Extraction Method
About 5–10mg of cells was suspended in 300µl of sterile distilled
water in a micro centrifuge tube. A series of three washes were
given with 900µl absolute ethanol and 50µl of 70% formic acid
followed by centrifugation at 12000 rpm for 2min. The pellet was
dissolved in 50µL acetonitrile and centrifuged at 12000 rpm for
2min. One microliter from the supernatant was loaded on target
and dried followed by analysis using MALDI-Biotyper Microflex,
Bruker, Germany. TheMALDI-biotyping for strain identification
was conducted at the MTCC, Council of Scientific and Industrial
Research-Institute of Microbial Technology (CSIR-IMTECH),
India.
Growth and Production Kinetics
The antimicrobial compound producing strain URID 12.1 was
inoculated in to 100ml of mTSB and incubated at 37◦C under
shaking condition. After every 4 h, 2ml of sample was collected
and centrifuged at 12000 rpm for 20min and the supernatant
was used to test the antimicrobial activity against the indicator
strain S. aureus MTCC 96 by cut-well agar diffusion assay and
the zone of inhibition in mm was noted. Simultaneously the
growth was also measured spectrophotometrically at OD 600 nm
and the activity was expressed as Arbitrary Unit per milliliter
(AU/mL); this value is the reciprocal of the highest two-fold
dilution exhibiting a zone of inhibition and estimated using the
formula (2n × 1000)/V (µl), where n= highest two-fold dilution
showing activity and V = volume used to test antimicrobial
activity.
Antimicrobial Activity Spectrum
The antimicrobial compound producing strain URID 12.1 was
inoculated into 100ml of mTSB and incubated at 37◦C for 44 h
and the supernatant was collected by centrifugation at 12000 rpm
for 20min. The supernatant was tested for antimicrobial activity
against the indicator strains (Table 1) by cut-well agar diffusion
assay and the zone of inhibition in mm was noted after 24–48 h
of incubation.
Solubility in Organic Solvents
The supernatant (10ml) was mixed with equal volume of organic
solvents (chloroform, methanol, and n-butanol), stirred for 4 h
and centrifuged at 12000 rpm for 20min. Both the soluble and
insoluble fractions were completely evaporated at 55◦C, dissolved
in 2ml of sterile Milli Q water and tested for activity against the
indicator strain MVRSA 4 by spot agar assay.
Effect of pH and Temperature
The effect of pH on the antimicrobial compound was determined
by adjusting the supernatant pH from 1.0 to 14.0 by using 1
N HCl and 1 N NaOH and incubated at 37◦C for 2 h, then
neutralized to pH 8.0 before testing the activity against the
indicator organisms (S. epidermidis ATCC 12228 and S. aureus
MTCC 737). The effect of temperature was determined by
incubating the aliquots of supernatant at 80◦C for 1 h, 100◦C for
30min and autoclaving for 20min. The untreated supernatant
was used as control.
Partial Purification of the Antimicrobial
Compound
URID 12.1 strain was grown at 37◦C for 44 h in mTS broth and
the cell free supernatant (CFS) was collected by centrifugation
at 12000 rpm, 4◦C for 20min. The CFS was subjected to acid
precipitation by adjusting the pH to 2.0 using 1 N HCl and
stirring in cold room overnight (Hernández et al., 2005; Ramya
et al., 2014). The precipitate was collected by centrifugation
at 12000 rpm, 4◦C for 20min and dissolved in 20mM sodium
phosphate buffer pH 8.0. The antimicrobial fractions were
extracted by stirring with equal volume of methanol (50% v/v)
for 3 h and centrifuged to collect the supernatant (Baindara
et al., 2013). The methanol was evaporated completely at
55◦C and the residue was dissolved in chloroform. Adsorption
chromatography was performed by using silica gel 230–400 mesh
equilibrated with chloroform.
Effect of Proteolytic Enzymes
Partially purified antimicrobial compound after adsorption
chromatography was treated with trypsin, final concentration of
10mg/mL at 37◦C for 12 h and proteinase K, final concentration
of 5mg/mL at 55◦C for 3 h (Shekh and Roy, 2012). The enzymes
after incubation were inactivated by heating at 80◦C for 10min
and the antimicrobial activity was tested against the indicator
strain MVRSA 4. The untreated sample and the enzyme alone
were used as positive and negative controls, respectively.
Effect of Surfactants
Partially purified antimicrobial compound after adsorption
chromatography was incubated at 37◦C for 5 h in the presence
of surfactants namely Sodium dodecyl sulfate (SDS), Tween 20,
Tween 80, and Triton X-100 at a final concentration of 1% (v/v)
(Kayalvizhi and Gunasekaran, 2010; Ramya et al., 2014) and
activity was tested against the indicator strain MVRSA 4. The
untreated sample and the surfactants at a final concentration
were used as positive and negative controls, respectively.
Effect of Metal Salts
The partially purified antimicrobial compound obtained after
adsorption chromatographywas treated withmetal salts (MgSO4,
FeSO4, MnCl2, AgNO3, ZnSO4, CdCl2, CuSO4,and CaCl2) at
a final concentration of 1mg/mL and kept for incubation at
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37◦C for 1 h (Ramya et al., 2014) before testing for activity
against the indicator strain MVRSA 4. Untreated sample and
the metal salts at final concentration were used as positive
and negative controls, respectively (Kayalvizhi and Gunasekaran,
2010).
Sodium Dodecyl Sulfate
(SDS)-Polyacrylamide Gel Electrophoresis
(PAGE) and Gel Overlay Assay
The biologically active semi purified antimicrobial compound
after adsorption chromatography was subjected to 15% SDS-
PAGE (Laemmli and Favre, 1973). After electrophoresis one
part of the gel with molecular marker and sample was used for
silver staining. The other part having sample was fixed with 25%
ethanol and 5% acetic acid for 30min. Zymogram treatments
were as per Bhunia et al. (1987) and Yamamoto et al. (2003).
Thin Layer Chromatography (TLC) and
Bioautography Assay
Partially purified biologically active antimicrobial compound
after adsorption chromatography was spotted on to silica gel 60
plate (7× 4 cm; layer thickness, 0.20mm, Merck) and developed
with chloroform-methanol-water (65:25:4) as mobile phase. One
part of the TLC plate was sprayed with ninhydrin (0.2%) to detect
the presence of amino acids. The other part was completely dried
of solvents before placing in a fresh Petri dish; the molten BHI
broth was pre-inoculated separately with the indicator strains
S. aureus MTCC 737 and MVRSA 4 along with Triphenyl
tetrazolium chloride (TTC) dye, poured on each TLC plate and
incubated at 37◦C overnight (Tabbene et al., 2009). The Rf value
of the antimicrobial compound was estimated. The Rf of the
detected spots is defined as the ratio between the distance traveled
by the compound divided by the distance traveled by the solvent.
Purification of the Antibacterial Compound
Produced by B. subtilis URID 12.1 by HPLC
Fractionation
Pooled active fractions after adsorption chromatography
were purified by reversed-phase high-performance liquid
chromatography on a C18 column (Zorbax, 5µm). Each run
included loading a 50µl sample to the column. HPLC-separation
was performed by using acetonitrile (with 0.1% trifluoroacetic
acid (TFA) and water gradient for 40min. The gradient used
was 0–50% acetonitrile for 18min at a flow rate of 1ml/min,
50–63% from 18 to 26min at 0.6ml/min, 63–68% from 26 to
38min at 0.4ml/min and 68–95% from 38 to 40min at 1ml/min.
Peaks eluting from the column were detected by the diode
array detection system at 210 nm. Fractions from multiple runs
were pooled and tested for the antimicrobial activity against the
indicator strain MVRSA 4.
Mass Spectrometry
The molecular mass of the purified compound was determined
by matrix-assisted laser desorption and ionization–time of flight
mass spectrometry. The mass spectrometry analysis of the
HPLC-purified fraction (6A) was repeatedly performed using
a Matrix-assisted Laser Desorption/Ionization-time of Flight
(MALDI-TOF) mass spectrometer (UltrafleXtreme, Bruker
Daltonics, Germany). An aliquot of 5µL sample was mixed with
5µl matrix (2,5-dihydroxy benzoic acid in acetonitrile with 0.1%
TFA). The sample was spotted onto the MALDI target and air-
dried. Mass spectrum was analyzed in the range of 500–3500
Da.
Determination of Minimum Inhibitory
Concentration (MIC) and Minimum
Bactericidal Concentration (MBC)
MIC determination was performed according to the Clinical
and Laboratory Standard Institute (CLSI) guidelines (CLSI,
2012).The MICs of the HPLC purified antimicrobial compound
against bacterial strains were determined by broth microdilution
method using BHI and cation-adjusted Mueller-Hinton broth
(CA-MHB) in 96 well plates. The MICs for S. aureus strains were
tested in CA-MH and for other strains in BHI broths since in
CA-MHB the growth of S. epidermidis ATCC12228 and VRE
strains couldn’t be visualized. Resazurin dye was added to each
well at a final concentration of 0.02%, as an indicator of growth.
The reversed-phase HPLC purified compound was diluted by
two-fold dilution in the range of 120–0.12µg/mL and inoculated
with 105 CFU/mL of the indicator strains prepared using
0.5 McFarland standards. The plates with 100µl appropriately
diluted samples were incubated at 37◦C with continuous shaking
(110 rpm) for 25 h and the lowest concentrations at which the
visible growth was not observed were recorded. The MBC
was determined by streaking 10µl of the dilutions from the
incubated plates to observe the colony formation and the lowest
concentration at which the colony formation was not observed
were recorded.
Haemolytic Assay
Human erythrocytes were harvested from whole blood by
centrifugation at room temperature for 10min at 2000 g. The
erythrocytes were washed three times with 10mM sodium
phosphate buffer pH 7.0 in 150mM NaCl phosphate buffered
saline (PBS). The pellet was resuspended in PBS to yield 20% (v/v)
erythrocytes/PBS suspension. The 20% suspension was diluted
1:5 in PBS. Equal volume of the antimicrobial compound in same
buffer was added at different concentrations ranging from 2.5
to 100µg/mL and incubated for 1 h at 37◦C. After incubation
the dilutions were centrifuged at room temperature for 5min
at 1500 g. The OD of the supernatant was measured at 450 nm
(Helmerhorst et al., 1999). Erythrocytes in PBS suspension with
1% (v/v) Tween 20 and buffer alone were used as positive and
negative controls, respectively. The % haemolysis was calculated
by using the formula
(
A450 of peptide treated sample − A450 of buffer treated sample
)
× 100
A450 of Tween 20 treated sample − A450 of buffer treated sample
RESULTS
Identification of the Producer Strain
Based on the 16S rDNA sequence (945 base pairs), the bacterial
strain which is a soil-isolate responsible for the production of
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FIGURE 1 | Phylogenetic tree showing the similarity of URID 12.1 among other Bacillus species. Pseudomonas mendocina was used as an outgroup.
the bioactive metabolite was identified as Bacillus atrophaeus
and assigned the GenBank accession number as JX156420.1 by
the NCBI. The phylogenetic tree analysis using Mega 5.0 has
shown the URID 12.1 more closely related to Bacillus subtilis
(Figure 1) with bootstrapping for 1000 replicates and displaying
for 100.
Identification of the Producer Strain by
MALDI-TOF (Matrix-assisted Laser
Desorption/Ionization-time of Flight)
Biotyper
The MALDI Biotyper identification of bacteria utilizes the
ribosomal protein fingerprint of the cell and relies on high
abundance proteins. The MALDI biotyping identified the
producer strain as Bacillus subtilis with a score of 1.905 which
shows the high level confidence of identification.
Production Kinetics
The antimicrobial activity of the URID 12.1 was tested against
the S. aureus MTCC 96 as the indicator strain. The production
of the antimicrobial compound started at 8 h of inoculation and
reached maximum by 40 h (26.0mm); however after 48 h, the
activity declined gradually (Figure 2). The maximum production
of the antimicrobial compound was at the late logarithmic
and early stationary phase. At 44 h the antimicrobial value was
detected to be 3200AU/mL.
Antimicrobial Activity Spectrum
The sensitivity of different microbial strains to the antimicrobial
compound produced by URID 12.1 was tested by cut well agar
diffusion assay using the CFS at 44 h of growth (Table 1). No
activity was observed against gram-negative strains (Table 1).
Effect of pH and Temperature
The antimicrobial compound was stable over a wide pH range
from 1 to 10, and at pH 12.0 there was a slight reduction
in the activity whereas there was a significant reduction in
the activity at pH 14.0. The antimicrobial compound was also
stable at different temperatures 80% activity was retained at
FIGURE 2 | Growth and production kinetics of URID 12.1; the
antimicrobial compound production is expressed as AU/mL.
80◦C for 1 h, 75% at 100◦C for 30min and 60% at 121◦C for
20min (Table 2). At acidic pH there is a slight reduction in
the activity at higher temperatures (100 and 121◦C) whereas
at alkaline pH there was significant reduction in the activity
with complete loss of activity at pH 12.0 after autoclaving
(Figure 3).
Effect of Proteolytic Enzymes, Organic
Solvents, Surfactants, and Metal Salts
The antimicrobial compound was tested for stability against
proteolytic enzymes, organic solvents, surfactants, and metal
salts (Table 3). The antimicrobial compound was stable after
treatment with proteolytic enzymes trypsin (10 mg/mL) and
proteinase K (5 mg/mL). The antibacterial activity against
MVRSA 4 was retained by trypsin and proteinase K treated
samples. The antimicrobial activity was not reduced by organic
solvents (50% v/v) and the surfactants at a final concentration
of 1%, indicating the hydrophobic nature of the compound. The
biological activity was not affected by the presence of metal salts
(Table 3).
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TABLE 2 | Effects of pH and Temperature on the antimicrobial activity.
Treatment Antimicrobial activity (%)
Untreated (Control) 100
pH
1.0 100
3.0 100
5.0 100
6.0 100
7.0 100
8.0 100
9.0 100
10.0 100
12.0 90
14.0 50
TEMPERATURE
80◦C for 1 h 80
100◦C for 30min 75
121◦C for 20min 60
FIGURE 3 | Effect of pH (3.0, 6.0, 8.0, and 12.0) and temperatures (100
and 121◦C) on the antimicrobial activity. (A,B) Effect on antimicrobial
activity after boiling for 30min at different pH values tested against methicillin
resistant S. epidermidis ATCC 12228 (MRSE) and S. aureus MTCC 737,
respectively. (C,D) Effect on antimicrobial activity after autoclaving at different
pH values against MRSE and S. aureus MTCC 737, respectively.
PAGE and Gel Overlay Assay
In SDS-PAGE the band less than 3.0 kDa has shown antimicrobial
activity (Figures 4A,B) against S. aureus MTCC 737. In the
Native PAGE the activity was observed at the top of the
resolving gel indicating may be the net positive charge of
the antimicrobial compound or aggregation in its native form
TABLE 3 | Effect of enzymes, solvents, surfactants, and metal salts.
Treatment Concentration Activity
Trypsin 10mg/mL +
Proteinase K 5mg/mL +
Surfactants (Tween 20, Tween 80,
and Triton X-100)
1% (v/v) +
Organic solvents (chloroform,
methanol, n-butanol)
50% (v/v) +
Metal salts (MgSO4, FeSO4, MnCl2,
AgNO3, ZnSO4, CdCl2, CuSO4, and
CaCl2)
1mg/mL +
+, indicates the retention of activity.
FIGURE 4 | (A) SDS-PAGE with molecular marker (lane M) and sample (lane
S). (B) Antimicrobial activity shown as zone of inhibition after SDS-PAGE and
zymogram. (C) Antimicrobial activity shown by Native PAGE and zymogram.
(Figure 4C). Zymogram showed activity against S. aureusMTCC
737.
Thin Layer Chromatography (TLC) and
Bioautography Assay
One part of the TLC plate was used for bioautography assay
and showed clear zone of inhibition (Figures 5A,B). The region
corresponding to the antimicrobial compound when sprayed
with 0.2% ninhydrin showed negative result. This may be due to
blocking of the N-terminal end by modification. The Rf value of
the spot was 0.8 (Figures 5A,B), the center of zone of inhibition
was taken as the distance traveled by the solute.
Purification of the Antimicrobial Compound
After acid precipitation the antimicrobial fractions were
extracted with methanol and adsorption chromatography was
performed using silica gel 230–400 mesh. Active fractions were
further purified by RP-HPLC on a C18 column; the eluting
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active fraction showed a retention time of 30.5min (Figure 6A,
encircled peak), indicating its non-polar nature.
Mass Spectrometry
The molecular mass of the purified compound determined by
MALDI was 842.37 Da (Figure 6B).
Determination of Minimum Inhibitory
Concentration (MIC) and Minimum
Bactericidal Concentration (MBC)
MIC of the HPLC purified antimicrobial compound against
different strains was calculated using two-fold micro broth
dilution method in 96 micro-well plates. The MIC values against
different strains were in the range of 0.3–16µg/mL (for MRSA 5)
in BHI and CA-MHB to 120µg/mL (for S. pyogenesNCIM 2608).
The MIC and MBC values determined against S. epidermidis
ATCC 12228 was 2 and 4µg/mL only in BHI broth. The MBC
values were in the range of 2–120µg/mL (Table 4). The MIC
values determined against E. faecalisATCC 29212 andmultidrug-
resistant VRE were 64 and >64µg/mL, respectively.
FIGURE 5 | (A) Bioautography assay showing zone of inhibition, against
S.aureus MTCC 737. (B) Bioautography assay (using the TTC dye) showing
antimicrobial activity against MVRSA 4 showing an Rf value 0.80.
Haemolytic Assay
As the antimicrobial compounds are used for biomedical
applications in treating infectious diseases it is important to
determine the extent of haemolysis on freshly drawn human
red blood cells. The antimicrobial compound has shown 4.69%
haemolysis at 100µg/ml concentration (Figure 7). Haemolysis
obtained by 1% Tween 20 was considered 100% haemolysis
(Figure 7).
DISCUSSION
The current observations from the literature survey indicate
that antibiotic resistance is rapidly evolving toward most known
antibiotics and the development of alternative antibiotics is
lagging far behind to combat serious infectious diseases.
The semi-purified antimicrobial substance was subjected
to various types of physico-chemical tests. After heat, acid,
and alkaline treatment, the inhibition zones produced by the
partially purified antimicrobial compound remained almost the
same (Table 1). This observation indicated that antimicrobial
compound was very stable. Similar observations were reported
in several cases, for example, Bacillocin Bb produced by the
Brevibacillus brevis Bb from soil (Faheem et al., 2007; Saleem
et al., 2009) is a bacteriocin like inhibitory substance (BLIS) that
is stable within the pH range of 1.0–9.0, resistant to heat (100◦C
for 30min), as well as detergents and organic solvents. The
adsorption chromatography- purified antimicrobial substance in
the present study also demonstrated resistance to surfactants and
organic solvents (Table 3).
The antimicrobial spectrum, pH-tolerance, thermal stability,
and resistance to proteolytic enzymes displayed by the
antimicrobial compound produced by URID 12.1 resemble
those of several other Bacillus-derived antibacterial peptides,
such as bacillocin Bb (Faheem et al., 2007; Saleem et al., 2009),
polyfermenticin SCD (Lee et al., 2001), pumilicin (Aunpad and
Na-Bangchang, 2007), brevicin AF01 (Guo et al., 2012). It was
reported recently (Guo et al., 2012) that the crude extract of
Paenibacillus OSY-SE was resistant to heat and changes in pH;
FIGURE 6 | (A) Reversed Phase HPLC chromatogram wherein the antimicrobial compound had a retention time of 30.5min (encircled peak). (B) MALDI-TOF analysis
showing the molecular mass as 842.37 Da.
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TABLE 4 | MIC and MBC values against different indicator strains in comparison with Subtilosin A, Sublancin 168, and S70-2.
Indicator strain MIC in BHI MBC MIC in CA-MHB MBC Sublancin 168 Subtilosin A S70-2
S. aureus ATCC 29213 – – 8.0 16.0 – – 250.0
S. aureus MTCC 737 (S. aureus ATCC 6538P) 0.3 7.5 4.0 8.0 – 100.0 –
Methicillin resistant S. aureus 2 [Barcode ID
1401101153]*
15.0 30.0 8.0 64.0 – – –
Methicillin and vancomycin resistant 4 S. aureus
[Barcode ID. 1312105888]/S. aureus 12600e
0.5 2.0 8.0 16.0 >100e – –
Methicillin resistant S. aureus 5 [Barcode ID
1312105847]*
– – 16.0 64.0 – – –
S. aureus GMC* 1.0 3.75 – – – –
S. epidermidis ATCC 12228 2.0 4.0 – – No activity – –
Methicillin resistant S. epidermidis 3
[1401101084]*
1.0 15.0 2.0 16.0 – – –
S. pyogenes NCIM 2608/S. pyogenes ATCC
19615e
120.0 120.0 – – 1.25 –
S. pyogenes MTCC 1928/S. pyogenes 49399e 60.0 >60 – 100.0e – –
M. luteus MTCC 2170 0.3 15.0 – – – – –
Bacillus wild-type culture** 30.0 120.0 – – – – –
E. faecalis ATCC 29212 64.0 – – 64.0 – – –
Vancomycin and methicillin resistant E. faecium
13 [Barcode ID 1312103662]*/E. faecalis ATCC
29219e/E. faecalis 19433N
>64.0 128.0 – >64 No activityN – 62.5
All values are expressed in (µg/mL).
*Clinical isolates were identified by an automated analyser Phoenix-100 (Becton Dickinson).
–Denotes “Not Determined.”
e,NDenotes the MIC produced by the antimicrobial substance against the indicator strain used shown in the first column.
**Environment isolate.
FIGURE 7 | Haemolytic activity of antimicrobial compound. One-hundred
microgram per milliliter of the HPLC-purified antimicrobial fraction showed
merely 4.69% hemolysis to cause any adverse haemolytic effects.
most of its antimicrobial activity was retained after holding at
80◦C for 24 h, autoclaving at 121◦C for 5min, and exposure to
pH 3.0, 5.0, and 9.0. Paenibacterin was resistant to treatment
with trypsin but not the other proteolytic enzymes like pronase
(Guo et al., 2012).
MRSA strains often causing nosocomial infections develop
resistance to antimicrobial compounds by modifying its cell
surface teichoic acid with D-alanine and show increased MIC
(Peschel and Collins, 2001; Peschel, 2002). In the present study,
altogether 11 Gram-positive bacteria tested were sensitive to
HPLC-purified antibacterial compound. The values of the MICs
were presented in Table 4. It is worth observing that the MICs
were comparable to the MICs produced by many antimicrobial
substances produced by Bacillus.
Out of 14 strains tested for the determination of MIC
values, the methicillin and vancomycin resistant S. aureus
(MVRSA) strain 4 was β-lactamase positive and resistant to
amoxicillin/clavulanate, cefoxitin (>8µg/ml), ciprofloxacin,
erythromycin, mupirocin, and teicoplanin, and vancomycin
(>16µg/ml); another clinical isolate MRSA 5 was β-lactamase
positive and cefoxitin (>8µg/ml) resistant. The MIC value
determined was 0.5µg/ml whereas the MBC value was
2.0µg/ml for MVRSA 4. High prevalence of mupirocin
resistance in S. aureus isolates from a pediatric population as
a result of mupirocin exposure in some areas of New York
was reported underlining the importance of antimicrobial
substance effective against mupirocin-resistant S. aureus
(Antonov et al., 2015). Likewise, the MRSA strain 2, resistant
to penicillin, amoxicillin/clavulanate, cefoxitin (>8µg/ml),
gentamicin (high level 500µg/ml), clindamycin, ciprofloxacin,
and erythromycin, the MIC values determined against it were
15.0 and 8.0µg/ml in BHI and CA-MHB, respectively. The
purified antimicrobial substance showed its strong antimicrobial
potential as reflected by low MIC values of 1.0 and 2.0µg/ml
using BHI and CA-MHB against the MRSE 3 (Table 4) which
besides being β-lactamase-positive is also resistant to cefoxitin
and penicillin, and against the S. epidermidis ATCC 12228,
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the MIC value was determined as 2.0µg/ml in BHI broth
(Table 4). The data analysis of the MIC values (Table 4) clearly
indicate either superior or comparable results for the purified
antimicrobial compound from the URID 12.1 when compared to
Bacillus derived antimicrobial compounds namely Subtilosin A,
Sublancin 168, and S70-2 (Paik et al., 1998; Shelburne et al., 2007;
Tabbene et al., 2010). The antimicrobial compound from URID
12.1 showed similar MIC and MBC values for two S. pyogenes
strains. For four S. aureus strains used in the study, the MIC
and MBC ratios are no more than 1:4 (Table 4) indicating the
compound’s potential to act as an antibacterial agent since any
antibacterial agent with an MBC no more than four times the
MIC is usually regarded as bactericidal (French, 2006).
Our result also showed that the HPLC-purified antimicrobial
compound had negligible hemolytic activity against 2% human
blood red cells even at 100µg/ml concentration (Table 4). In
this context, it is worth mentioning that out of 14 strains used
in the present study, for 11 strains, the MIC values recorded
were less than or equal to 30µg/ml. The lichenicidin from B.
licheniformis DSM 13 was reported to have inhibited S. aureus,
S. pyogenes, B. subtilis but neither caused hemolysis nor inhibited
the growth of gram-negative bacteria (Dischinger et al., 2009).
Lichenicidin might not be a lipopeptide antibiotic that generally
causes hemolysis (Volpon et al., 1999; Leclère et al., 2005). The
lack of haemolytic activity might indicate that the antimicrobial
compound is probably devoid of haemolytic/cytotoxic activity;
the same inference was drawn for the S07-2 which lacked
haemolytic activity even at the concentration of 1000µg/ml
(Tabbene et al., 2010). Our study has unequivocally established
the fact that the antimicrobial compound although possesses a
narrow-spectrum of antibacterial activity yet it has high antibiotic
potential; however further studies are needed to determine the
in vivo efficacies and cytotoxic effects for their utility in clinical
applications. After a critical reconnoitering of molecular masses
and the antimicrobial profiles and potentials of all the previously
reported Bacillus-derived antimicrobial compounds, no anti-
Staphylococcus and anti-Streptococcus pyogenes compound of
molecular mass of range between 800 and 850 Da with a lowMIC
values and high proteolytic stability was found to be reported
and thus promises to be a novel antimicrobial principle. To
the best of our knowledge, an antimicrobial agent or principle
possessing significant activity against multidrug-resistant strains
and molecular weight as low as 0.84 kDa has not been reported
earlier from any wild-type Bacillus sp.
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